慢性リンパ球性白血病における腫瘍微環境と標的治療の役割

Khalil Saleh¹, Ahmadreza Arbab², Nadine Khalife³

¹International Department, Gustave Roussy Cancer Campus, 94800 Villejuif, France.

Current issues in molecular biology

|August 27, 2025

まとめ

慢性リンパ球性白血病 (CLL) の治療は,ブルートンで進化しています.

科学分野:

血液学
腫瘍学
分子生物学

背景:

慢性リンパ球性白血病 (CLL) は,成熟したB細胞の増殖によって定義される大流行性白血病です.
腫瘍の微小環境 (TME) は,CLL細胞の生存と増殖に不可欠です.
最近の薬の承認は,CLLの管理戦略を大幅に変更しました.

研究の目的:

CLL腫瘍のマイクロ環境の重要な構成要素をレビューする.
CLLの現在の標的治療データを要約する.
CLLにおけるブルトンチロシンキナーゼ (BTK) とBCL-2阻害体の役割を強調する.

主な方法:

CLL腫瘍の主要成分に関する文献レビュー.
BTKとBCL-2阻害剤に焦点を当てた標的療法に関するデータの分析
TME内のBTKとBCL-2を含む信号経路の要約

主要な成果:

BTKとBCL-2阻害剤は,CLLの主要な治療クラスです.
これらの阻害剤は,治療を必要とする患者に対する第一線治療として承認されています.
BTKとBCL-2は,TME媒介のシグナル伝達経路において重要な役割を果たします.

結論:

ターゲットを絞った治療法,特にBTKとBCL-2阻害剤は,CLL治療に変化をもたらしました.
TMEの理解は,CLLの管理におけるこれらの標的治療の最適化に不可欠です.
TMEの成分と標的薬に対するさらなる研究は,CLLの治療パラダイムを精錬し続けるでしょう.

キーワード:

BCL-2 について BTK について CAR T細胞バイスペシフィック慢性リンパ球性白血病腫瘍の微小環境

さらに関連する動画

07:49

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model

Published on: April 13, 2015

20.3K

09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

21.5K

関連する概念動画

02:17

The Tumor Microenvironment

6.8K

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

6.8K

02:57

Targeted Cancer Therapies

7.8K

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

7.8K

01:27

Tumor Immunotherapy

659

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

659

02:40

Cancer Stem Cells and Tumor Maintenance

5.0K

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...

5.0K

02:50

Combination Therapies and Personalized Medicine

5.1K

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...